患者与风湿科医生对类风湿关节炎低剂量糖皮质激素疗效与安全性的认知调查
该国际调查通过在线问卷评估1221例曾暴露于糖皮质激素的RA患者与414名风湿科医生对低剂量GCs疗效与安全性的看法。双方对疗效认可度高(至少70%认为起效快且有效),但患者中半数报告曾发生严重不良事件、83%存在安全担忧,风湿科医生对内分泌、眼科及皮肤不良事件发生率的估计也偏高,均远超已发表证据,提示需加强教育并开展真实风险研究。
要点
- 患者与风湿科医生均高度认可低剂量GCs治疗RA的快速有效性。
- 患者安全担忧突出:半数报告严重不良事件,83%表达安全顾虑。
- 医生对低剂量GCs部分不良事件发生率的估计远超已发表证据。
核心结论
- 患者与风湿科医生对低剂量GCs疗效满意度均高,但对安全性的担忧远超已发表证据,可能影响该药的合理使用。
研究设计与样本
- 国际在线问卷调查,通过国家患者组织与风湿病学会发放,使用SurveyMonkey®、MediGuard.org及GLORIA研究网站。
- 共纳入1221例曾暴露于GCs的RA患者与414名风湿科医生完成调查。
主要发现
- 至少70%的患者与风湿科医生认为低剂量GCs对控制RA症状体征非常快速且有效。
- 半数患者报告曾因GCs发生严重不良事件,83%的患者表达对安全性的担忧。
- 多数风湿科医生基于热图估计内分泌、眼科及皮肤不良事件影响超过4%接受低剂量GCs治疗2年的患者。
关键数值与推荐
- 至少70%的受访者认可低剂量GCs快速有效控制RA症状体征。
- 多数风湿科医生估计内分泌、眼科及皮肤不良事件影响>4%的低剂量GCs治疗2年患者。
临床怎么用
- 临床沟通中需向患者客观说明低剂量GCs的真实获益与风险,避免因过度担忧影响治疗依从性。
- 对医生开展基于证据的低剂量GCs安全性教育,纠正对不良事件发生率的高估。
局限性
- 原文未报告调查回收率、应答者代表性及问卷效度等局限信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the current perspectives of patients and health professionals regarding the efficacy and safety of low-dose glucocorticoids (GCs) in RA. METHODS: Two online surveys were disseminated to patients and health professionals, in their native language, through national patient organizations and national rheumatology medical societies, respectively. SurveyMonkey®, MediGuard.org and the Glucocorticoid Low-dose Outcome in RA Study (GLORIA) website were used to offer and deliver these surveys. RESULTS: A total of 1221 RA patients with exposure to GCs, and 414 rheumatologists completed the surveys. Patients and rheumatologists reported high levels of agreement regarding the efficacy of low-dose GCs: at least 70% considered that they are very rapid and effective in the control of signs and symptoms of RA. However, half of the patients also reported having suffered serious adverse events with GCs, and 83% described concerns about safety. The majority of rheumatologists estimated that endocrine, ophthalmologic and cutaneous adverse events affect >4% of all patients treated with low-dose GCs for 2 years, based on a heat map. CONCLUSIONS: RA patients with self-reported exposure to GCs express high levels of satisfaction with low-dose GCs efficacy, as do rheumatologists. However, both expressed excessive concerns regarding the safety of GCs (greatly exceeding the published evidence data), which may compromise the optimal use of this medication. This study indicates that there is an unmet need for appropriately designed prospective trials that shed light on the real risk associated with low-dose GCs, as well as a need for renovated educational programs on the real benefits and harms of low-dose GCs, for both patients and physicians.
引用
- Santiago T, Voshaar M, de Wit M, et al. Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis-an international survey within the GLORIA study. Rheumatology (Oxford). 2021. PMID: 33394036. doi:10.1093/rheumatology/keaa785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。